NR3C1 and COVID-19: While antiviral drugs, antibiotics, and antimalarial have shown little to no clinical benefit in COVID-19 patients32–34, modulation of host inflammatory responses with drugs that inhibit IL-6 signaling (tocilizumab) or stimulate GR activity (dexamethasone) have been suggested to improve clinical outcomes in critically ill patients6,35 negative results have also been reported36.